Introduction

- Patients with MPS I continue to experience pain and symptoms that affect function despite disease-modifying treatment with haematopoietic stem cell transplantation (HSCT) and enzyme replacement therapy (ERT).1,2
- Pentosan polysulfate sodium (PPS), a semisynthetic polysaccharide that resembles glycosaminoglycans (GAGs), has been shown to improve pain and function in patients with MPS I, MPS II and 61,6,7

PPS is being evaluated as an adjunctive therapy to ERT and/or HSCT in the PARA_MPS1_001 open-label, single-centre, phase 2 pilot study.

Objectives

- Primary: Safety and tolerability of PPS.
- Secondary and exploratory: Patient reported outcomes (PROs) measuring pain, function, fatigue, quality of life (QOL); physical tests of mobility and dexterity; and pharmacokinetics (PK); changes in biomarkers signaling cartilage degeneration, bone turnover and inflammation.

Methods

Inclusion Criteria:
- Age ≥5 years, documented diagnosis of MPS I (genetic testing and/or enzyme activity), previously received HSCT and/or ERT.

Study Design:
- Patients are sequentially allocated to Cohort 1 or Cohort 2 and administered PPS subcutaneous (SC) injections once weekly to Week 12 then fortnightly to Week 48. Eligible patients may continue in the study for an additional 6 months.

Assessments:
- Safety: Incidence of treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), and clinically significant changes from baseline in clinical laboratory data.
- Efficacy: Informed by global clinicians and an MPS patient focus group: Physical tests: 2- and 6-minute walk test (2/6MWT); 9-hole peg test (9HPT), Gait, Stairs, Gower, Chair (GSSGC); joint passive range of motion (ROM) and grip test. PROs: Paediatric, proxy, or adult Patient-Reported Outcomes Measurement Information System (PROMIS) - pain intensity, pain interference, pain behavior, fatigue, upper extremity and mobility/physical function with mobility aid short forms; and patient global impression of change (PGIC). Patients under 18 years had parent ‘proxy’ questionnaires completed as well as self-assessment.
- PK: PPS concentration in blood before and after repeat PPS administration (predose and 2, 4, and 6 hours post dose of dose 1, 2, 3).
- Biomarkers: Urinary GAG (fragment and total GAG), and serum and urine inflammation, cartilage degeneration, bone turnover.

PARA_MPSI_001 Study Design

Week 48

Week 14

Week 12

Day 1

First PPS injection

PPS injections once weekly

PPS injections every 2 weeks

Last PPS injection

Day -28 to -1

EOS = end of study; PPS = pentosan polysulfate sodium

Results

Patient Population and Disease Characteristics:
Three white, female, right-handed patients with MPS I-Hurler ages 14 (01-102), 15 (01-201) and 19 (01-101) years are enrolled into the study. All were diagnosed under 2 years of age and underwent HSCT within 6 months of diagnosis. Two patients (01-102, 01-201) received ERT for 6 months, commencing 4 and 2 months prior to HSCT respectively. Patients 01-101 and 01-102 received 0.75mg/kg, and patient 01-201 received 1.5mg/kg. All patients had musculoskeletal symptoms, pain, and reduced function at study entry. Analgesics were not permitted within 24 hours before assessments. Patient 01-101 had pre-planned bilateral knee surgery at week 15 and 1 finger surgery at week 20.

Safety:
Of the 11 TEAEs, 2 were considered related to study drug (moderate pre-syncope and mild injection site bruising, both in the same patient and recovered). All TEAEs have been deemed mild to moderate and resolved, with no SAEs reported.

Biomarkers:

- Urinary GAGs

- All patients had a decrease (improvement) in the MPS I signature oligosaccharide GAG fragments (sulfated disaccharide) (UA-HNAc8) from baseline to week 25, with the greatest improvement seen in patient 01-102, who had a 40% drop from the highest baseline levels.
- There was a modest increase in total uGAGs (dimethylene blue (DMB)) for patients, and a decrease in patient 01-102.
Results (cont.)

Pharmacokinetics:

- Overall, most of the biomarkers (inflammatory, cartilage degeneration and bone turnover) evaluated in all patients have indicated either no change or a reduction in levels at week 25 compared to baseline. This is an indication that PPS has the potential to modulate the inflammatory and joint degenerating biomarkers that are associated with arthralgia in MPS I patients.

- The PK characteristics were reproducible, demonstrated consistent rapid rise and fall in plasma concentration that was proportionate to dose administered (mg/kg). Plasma concentration returned to baseline prior to the next dose/assessment and followed characteristics of repeated single dose exposure.

- There was a trend toward improvement in 2/6MWT from baseline to week 25. Higher functioning patients at baseline demonstrated modest improvement.

- 01-102 was unable to complete the full 6MWT at baseline and week 6 due to back pain and fatigue, however was able to complete the full 6 minutes at subsequent visits.

- At week 25, patients exhibited either improvement or no significant change on most parameters. Exception was 01-101, who had greater shoulder abduction ROM at baseline than the other patients, and experienced decreased shoulder abduction movement at week 25. Knee extension remained unchanged in 2 of the 3 patients, and significantly improved in the third patient. Patient 01-201, receiving the high dose (1.5 mg/kg) had improved ROM on all joints assessed.

- At baseline, all patients took longer to complete the test than the average for age/gender, with two patients taking greater than 2 standard deviations longer. At week 25, patients were generally stable or improved in the test (exception was patient 01-101 non-dominant hand, possibly influenced by Lj index finger surgery at week 20).

- All patients demonstrated overall improvement in the GSGC qualitative global score with improvements ranging from 25%-39% over baseline at week 25.

- Times to complete the tests were faster at week 25 than baseline, with the exception was 01-101 (who had a faster time at study entry, and had bilateral knee surgery at week 15), and increased seconds in Gower and chair activities at week 25 (data not shown).

Grip strength: No significant changes were observed from baseline to week 25.
### Results (cont.)

#### PROMIS

<table>
<thead>
<tr>
<th></th>
<th>Pain Intensity</th>
<th>Pain Interference</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>PROMIS Score</td>
<td>PROMIS Score</td>
</tr>
</tbody>
</table>

- **At week 25**, all patients and proxies experienced improvements in pain intensity and pain interference scores between baseline and week 25. Two patients had no pain at week 25.

- **Exception** was patient 01-201, whose baseline pain intensity assessment was significantly lower than subsequent assessments. This patient’s pain intensity peaked at week 6 and then gradually decreased.

- Subcutaneous PPS was well tolerated at doses of 0.75 and 1.5 mg/kg out to 24 weeks of continuous dosing.

- **Universally**, all patients and proxies reported improvements in pain and function scores out to week 25.

- At week 25, all patients experienced improvement in fatigue scores, which was mirrored by the proxy reports.

- **Both patients and proxies** reported improved mobility scores by week 25.

- **All patients and proxies** reported improved function scores by week 25.

- **All proxies reported** improvements in upper extremity (UE) function scores, although on self-report only 2 of the 3 patients reported improved UE function score at week 25.

#### Conclusions

- **MPS I patients continue to experience pain and arthropathy following HSCT and/or ERT**. These often-debilitating symptoms significantly impact physical function and quality of life. PPS may address this unmet medical need and provide improvement in pain and function. Further studies are warranted to continue investigation of PPS in MPS I.

### References

7. Donten-Viac F, Phillips B, Green J, et al. Changes in the profile of biomarkers suggest that PPS has the potential to modulate the inflammatory and joint degrading biomarkers that are associated with arthralgia in MPS I patients.

### Disclosures

**PARA_MPSI_001 is funded by Paradigm Biopharmaceuticals Ltd. Michael Imperiale and Sharon Charles are employees of Paradigm Biopharmaceuticals Pty Ltd. The study was approved by WHCN Human Research Ethics Committee, and all patients provided written informed consent to participate in the study.**

### Funding

**Funding** for PARA_MPSI_001 is funded by Paradigm Biopharmaceuticals Ltd. Paradigm Biopharmaceuticals Ltd is developing PPS for the treatment of complications of mucopolysaccharidosis including pain and function. The author(s) confirm(s) independence from the Sponsor; the content of this presentation has not been influenced by the Sponsor.

### Acknowledgements

The authors acknowledge and thank clinical trial patients and staff for their time and contribution to MPS research. The authors acknowledge Maria Fuller, PhD, FFCS (BCP), Clinical Scientist, Genetics and Molecular Pathology, SA Pathology, Adelaide; Michael A. Eldon, PhD, FCP, Partner, Expert Consultant in Clinical Pharmacology, Pharmacokinetics, and Pharmacometrics, NDA Partners, LLC; Beth Leiro, BiSP, Clinical Outcome Consultant; Catherine Stapledon, PhD and Translational Scientist at Paradigm; and Divya Nawari, Biometrics Manager at Paradigm.